There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoGen (NASDAQ: IMGN), Tesaro (NASDAQ: TSRO) and SELLAS Life Sciences Group Inc (NASDAQ: SLS) with bullish sentiments.
ImmunoGen (NASDAQ: IMGN)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on ImmunoGen (NASDAQ: IMGN), with a price target of $18. The company’s shares closed yesterday at $10.68.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.5% and a 48.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on ImmunoGen is Moderate Buy and the average price target is $14.80, representing a 38.6% upside.
In a report issued on May 30, Canaccord Genuity also maintained a Buy rating on the stock with a $20 price target.
See today’s analyst top recommended stocks >>
Tesaro (NASDAQ: TSRO)
H.C. Wainwright analyst Edward White maintained a Buy rating on Tesaro (NASDAQ: TSRO) today and set a price target of $104. The company’s shares closed yesterday at $42.28, close to its 52-week low of $42.13.
According to TipRanks.com, White is a 5-star analyst with an average return of 26.0% and a 55.6% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Synthetic Biologics Inc, and Karyopharm Therapeutics.
Currently, the analyst consensus on Tesaro is Moderate Buy and the average price target is $85.43, representing a 102.1% upside.
In a report issued on May 31, Citigroup also reiterated a Buy rating on the stock with a $100 price target.
SELLAS Life Sciences Group Inc (NASDAQ: SLS)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on SELLAS Life Sciences Group Inc (NASDAQ: SLS) today and set a price target of $11. The company’s shares closed yesterday at $5.55, close to its 52-week low of $3.43.
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -10.9% and a 34.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Strata Skin Sciences Inc.
Currently, the analyst consensus on SELLAS Life Sciences Group Inc is Moderate Buy and the average price target is $12, representing an 116.2% upside.
In a report issued on June 1, Maxim Group also assigned a Buy rating to the stock with a $13 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
